{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:25:29Z","timestamp":1790799929965,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.ygyno.2011.08.014","type":"journal-article","created":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T22:10:40Z","timestamp":1315951840000},"page":"10-14","source":"Crossref","is-referenced-by-count":228,"title":["An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)"],"prefix":"10.1016","volume":"124","author":[{"given":"Dennis S.","family":"Chi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario M.","family":"Leitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem R.","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.08.014_bb0005","series-title":"Cancer facts & figures","year":"2010"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0010","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0015","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0020","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Gynecologic oncology group. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0025","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"European Organization for Research and Treatment of Cancer \u2014 Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0035","first-page":"383","article-title":"Staging announcements: FIGO cancer committee","volume":"25","year":"1986","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0040","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00000658-200206000-00007","article-title":"Quality of complication reporting in the surgical literature","volume":"235","author":"Martin","year":"2002","journal-title":"Ann Surg"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0045","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ygyno.2004.01.029","article-title":"Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach","volume":"94","author":"Chi","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0055","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","article-title":"Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels","volume":"19","author":"Rustin","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0060","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0065","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1996","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0070","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0075","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/1097-0142(197803)41:3<936::AID-CNCR2820410322>3.0.CO;2-B","article-title":"Adjuvant chemotherapy","volume":"41","author":"Skipper","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0080","first-page":"1727","article-title":"A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate","volume":"63","author":"Goldie","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0085","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0090","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0100","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/gyno.2001.6313","article-title":"Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with \u201cbiological aggressiveness\u201d and survival?","volume":"82","author":"Eisenkop","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0105","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3346\/jkms.2010.25.7.1034","article-title":"Feasibility and safety of extensive upper abdominal surgery in elderly patients with advanced epithelial ovarian cancer","volume":"25","author":"Lim","year":"2010","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0110","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2010.05.031","article-title":"The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas","volume":"119","author":"Chi","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0120","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ygyno.2006.06.004","article-title":"The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns","volume":"103","author":"Park","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0125","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.08.014_bb0135","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811006998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811006998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T03:52:03Z","timestamp":1543549923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811006998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0090825811006998"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.08.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}